All In MedTech

FDA Clearance Tracker · P080025-S248

InterStim® Therapy System, Verify® Evaluation System

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Mar 14, 2023 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Mar 14, 2023

Approved

Time to decision

428 days

Received Jan 10, 2022. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track

Device class

Class III

The decision

FDA number
P080025-S248
Device name
InterStim® Therapy System, Verify® Evaluation System
Applicant location
Minneapolis, MN
Received
Jan 10, 2022
Decided
Mar 14, 2023
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Change Design/Components/Specifications/Material
Original approval
P080025

Device type

Device class
Class III
Regulation
21 CFR 876.5270

Every decision under product code QON

FDA's approval statement

As written in FDA's record.

Approval with conditions for Medtronics updated use of third party applications on the CT900 and HH90 devices.

Source documents

Other decisions for Medtronic Neuromodulation

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

2 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.